STOCK TITAN

[Form 3] Corvus Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Corvus Pharmaceuticals, Inc. (CRVS) filed an Initial Statement of Beneficial Ownership (Form 3) reporting that David Scott Moore is a director and that, as of the 10/02/2025 event date, no securities are beneficially owned by him. The filing was signed on 10/06/2025 by an attorney-in-fact and includes a power of attorney exhibit.

Corvus Pharmaceuticals, Inc. (CRVS) ha presentato una Dichiarazione iniziale di proprietà beneficiaria (Modulo 3) riferendo che David Scott Moore è un amministratore e che, alla data dell'evento 10/02/2025, nessun titolo è detenuto da lui in qualità di beneficiario. La presentazione è stata firmata il 10/06/2025 da un mandatario e include un allegato di procura.
Corvus Pharmaceuticals, Inc. (CRVS) presentó una Declaración inicial de propiedad beneficiosa (Formulario 3) informando que David Scott Moore es director y que, a la fecha del evento 10/02/2025, no posee valores de forma beneficiosa por él. La presentación fue firmada el 10/06/2025 por un apoderado y incluye un poder.

Corvus Pharmaceuticals, Inc. (CRVS)초기 이익 소유 보고서(Form 3)를 제출했으며, David Scott Moore가 이사이고, 이벤트 날짜 10/02/2025에 그가 직접 또는 수익적으로 보유한 증권이 없다고 보고했고, 서류는 10/06/2025에 대리인이 서명했으며 위임장 부록을 포함한다.

Corvus Pharmaceuticals, Inc. (CRVS) a déposé une Déclaration initiale de propriété bénéficiaire (Formulaire 3) indiquant que David Scott Moore est administrateur et que, à la date de l'événement 10/02/2025, aucun titre n’est détenu par lui en tant que bénéficiaire. Le dépôt a été signé le 10/06/2025 par un mandataire et comprend une pièce d'attestation de procuration.
Corvus Pharmaceuticals, Inc. (CRVS) hat eine Erste Erklärung des wirtschaftlich Berechtigten (Formular 3) eingereicht und berichtet, dass David Scott Moore Vorstandsmitglied ist und dass zum Zeitpunkt des Ereignisses am 10/02/2025 keine Wertpapiere in Eigentum des Betroffenen stehen. Die Einreichung wurde am 10/06/2025 von einem Bevollmächtigten unterzeichnet und enthält einen Vollmachtsnachweis.
قامت شركة Corvus Pharmaceuticals, Inc. (CRVS) بتقديم بيان أول للملاك المستفيد (النموذج 3) يفيد بأن ديفيد سكوت مور هو عضو مجلس إدارة وبأنه حتى تاريخ الحدث 10/02/2025، لا يملك أي أوراق مالية كمالك مستفيد. تم توقيع الملف في 10/06/2025 من قبل وكيل قانوني ويتضمن مذكّرة توكيل.
Corvus Pharmaceuticals, Inc. (CRVS) 已提交一份初始受益所有权声明(表格3),报告称David Scott Moore为董事,并且在事件日日期 10/02/2025 时,该人并无受益所有的证券。该 filing 由一名代理人于 10/06/2025 签署,并包含授权书附件。
Positive
  • Disclosure completed for a director under Section 16
  • No reportable securities owned by the director as of 10/02/2025
Negative
  • None.

Insights

Director appointment shows governance disclosure with no immediate equity stake.

As reported, David Scott Moore is identified as a director and filed an initial Form 3 that states no securities are beneficially owned as of the 10/02/2025 event date. This indicates he held no reportable equity or derivative positions at that cut-off.

Key dependencies include any subsequent Form 4 filings if equity is later acquired; investors should note the signature date 10/06/2025 and expect additional Section 16 reporting if holdings change within statutory windows.

Corvus Pharmaceuticals, Inc. (CRVS) ha presentato una Dichiarazione iniziale di proprietà beneficiaria (Modulo 3) riferendo che David Scott Moore è un amministratore e che, alla data dell'evento 10/02/2025, nessun titolo è detenuto da lui in qualità di beneficiario. La presentazione è stata firmata il 10/06/2025 da un mandatario e include un allegato di procura.
Corvus Pharmaceuticals, Inc. (CRVS) presentó una Declaración inicial de propiedad beneficiosa (Formulario 3) informando que David Scott Moore es director y que, a la fecha del evento 10/02/2025, no posee valores de forma beneficiosa por él. La presentación fue firmada el 10/06/2025 por un apoderado y incluye un poder.

Corvus Pharmaceuticals, Inc. (CRVS)초기 이익 소유 보고서(Form 3)를 제출했으며, David Scott Moore가 이사이고, 이벤트 날짜 10/02/2025에 그가 직접 또는 수익적으로 보유한 증권이 없다고 보고했고, 서류는 10/06/2025에 대리인이 서명했으며 위임장 부록을 포함한다.

Corvus Pharmaceuticals, Inc. (CRVS) a déposé une Déclaration initiale de propriété bénéficiaire (Formulaire 3) indiquant que David Scott Moore est administrateur et que, à la date de l'événement 10/02/2025, aucun titre n’est détenu par lui en tant que bénéficiaire. Le dépôt a été signé le 10/06/2025 par un mandataire et comprend une pièce d'attestation de procuration.
Corvus Pharmaceuticals, Inc. (CRVS) hat eine Erste Erklärung des wirtschaftlich Berechtigten (Formular 3) eingereicht und berichtet, dass David Scott Moore Vorstandsmitglied ist und dass zum Zeitpunkt des Ereignisses am 10/02/2025 keine Wertpapiere in Eigentum des Betroffenen stehen. Die Einreichung wurde am 10/06/2025 von einem Bevollmächtigten unterzeichnet und enthält einen Vollmachtsnachweis.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Moore David Scott

(Last) (First) (Middle)
C/O CORVUS PHARMACEUTICALS, INC.
901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/02/2025
3. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24.1 - Power of Attorney
No securities are beneficially owned.
/s/ Leiv Lea, as Attorney-in-Fact for David Scott Moore 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 for Corvus Pharmaceuticals (CRVS) report?

The Form 3 reports that David Scott Moore, identified as a director, does not beneficially own any securities as of 10/02/2025.

When was the Form 3 signed for the CRVS filing?

The filing was signed by an attorney-in-fact on 10/06/2025.

Does this Form 3 show any stock options or derivative holdings for CRVS director?

No. The filing explicitly states no securities are beneficially owned, and no derivative or option positions are listed.

Will there be additional filings if the director acquires shares?

Yes. Any subsequent acquisition by the director would typically be reported on a Form 4 under Section 16 within the required reporting window.

Who signed the Form 3 for David Scott Moore?

The Form 3 was signed as /s/ Leiv Lea, as Attorney-in-Fact for David Scott Moore on 10/06/2025.
Corvus Pharmaceu

NASDAQ:CRVS

CRVS Rankings

CRVS Latest News

CRVS Latest SEC Filings

CRVS Stock Data

520.11M
57.95M
3.96%
56.24%
12.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
BURLINGAME